The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy in adult patients with relapsed or refractory (r/r) CD19-positive B-cell Non-Hodgkin Lymphoma (B-NHL) or B-cell Leukemia. The main questions it aims to answer are: * What are the safety and tolerability profiles of GI001, specifically regarding the incidence of Dose-Limiting Toxicities (DLTs) and the determination of the Maximum Tolerated Dose (MTD)? * What is the preliminary efficacy of GI001, measured by Objective Response Rate (ORR), Complete Response Rate (CRR), and Duration of Response (DOR)? * What are the pharmacokinetic (expansion and persistence of CAR-T cells) and pharmacodynamic (cytokine changes) characteristics of GI001? Participants will: * Undergo a screening process (D-30 to D-3) and baseline evaluation to ensure eligibility, including confirmation of CD19-positive disease. * Receive a single intravenous infusion of GI001 at one of four designated dose levels (1E8, 3E8, 7E8 or 1E9 TU) following an "Accelerated Titration" and "3+3" dose-escalation design. * Remain hospitalized for at least 14 days post-infusion for intensive safety monitoring, specifically for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). * Provide multiple blood, saliva, and urine samples for pharmacokinetic (PK), pharmacodynamic (PD), and exploratory analysis (including immunogenicity and viral shedding). * Participate in efficacy and safety follow-ups through Month 24, followed by a long-term safety follow-up for up to 15 years.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timeframe: Baseline up to 24 months post-infusion
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Timeframe: D0 up to D28
Number of Participants with Clinically Significant Changes in Vital Signs
Timeframe: Baseline up to 24 months post-infusion
Number of Participants with Clinical Laboratory Abnormalities
Timeframe: Baseline up to 24 months post-infusion
Number of Participants with Clinically Significant Abnormal Physical Examination Findings
Timeframe: Baseline up to 24 months post-infusion
Changes in 12-Lead Electrocardiogram (ECG) Parameters from Baseline
Timeframe: Baseline up to 24 months post-infusion
Changes in Eastern Cooperative Oncology Group (ECOG) Performance Status Score from Baseline
Timeframe: Baseline up to 24 months post-infusion